Comparative Pharmacology
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus UCEPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus UCEPHAN.
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE vs UCEPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
UCEPHAN (eculizumab) is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and terminal complement-mediated cell lysis.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
500 mg orally every 12 hours or 250 mg orally every 8 hours.
None Documented
None Documented
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Terminal elimination half-life is 2.1 ± 0.5 hours in adults with normal renal function; prolonged to 20–50 hours in severe renal impairment (CrCl <10 mL/min).
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Approximately 70–80% of an administered dose is eliminated unchanged in urine via glomerular filtration and tubular secretion; the remainder (20–30%) is eliminated via biliary/fecal routes, with <5% as metabolites.
Category D/X
Category C
Antibiotic
Antibiotic, Cephalosporin